The curcumin analog DM-1 induces apoptotic cell death in melanoma

Tumor Biology

Volumn 34, Issue 2, 2013, Pages 1119-1129

  Faião Flores, Fernanda ^a,b   Suarez, José Agustín Quincoces ^c   Maria Engler, Silvya Stuchi ^b   Soto Cerrato, Vanessa ^d   Pérez Tomás, Ricardo ^d   Maria, Durvanei Augusto ^a  

^a INSTITUTO BUTANTAN   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Universidade Bandeirante de Sao Paulo   (Brazil)

^d UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Apoptosis; Curcumin analog; Dacarbazine (DTIC); DM 1; Melanoma; Synergism

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE 8; CURCUMIN DERIVATIVE; CYCLIN D1; DACARBAZINE; KI 67 ANTIGEN; LIPOCORTIN 5; SODIUM 4 [5 (4 HYDROXY 3 METHOXYPHENYL) 3 OXO PENTA 1,4 DIENYL] 2 METHOXYPHENOLATE; TUMOR NECROSIS FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; ALKYLATING AGENT; CURCUMIN; FREE RADICAL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER SURVIVAL; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIPID PEROXIDATION; MELANOMA; MONOTHERAPY; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR NECROSIS; TUMOR VOLUME; ANIMAL; CELL PROLIFERATION; COMPARATIVE STUDY; DRUG EFFECT; METABOLISM; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOLOGY; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BLOTTING, WESTERN; CELL PROLIFERATION; CURCUMIN; DACARBAZINE; FLOW CYTOMETRY; FREE RADICALS; HUMANS; LIPID PEROXIDATION; MELANOMA; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; TUMOR CELLS, CULTURED;

MLCS; MLOWN;

EID: 84877133647     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0653-y     Document Type: Article

References (44)

1. Garbe C, Leiter U. Melanoma epidemiology and trends. Clin Dermatol. 2009;27:3-9.
2. Jilaveanu LB, Aziz SA, Kluger HM. Chemotherapy and biologic therapies for melanoma: do they work? Clin Dermatol. 2009;27:614-25.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2012;62:10-29.
4. Schadendorf D, Ugurel S, Schuler-Thurner B, Nestle FO, Enk A, Bröcker EB, Grabbe S, Rittgen W, Edler L, Sucker A, Zimpfer-Rechner C, Berger T, Kamarashev J, Burg G, Jonuleit H, Tüttenberg A, Becker JC, Keikavoussi P, Kämpgen E, Schuler G. DC study group of the DeCOG. Dacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOG. Ann Oncol. 2006;17:563-70.
5. Eigentler TK, Caroli UM, Radny P, Garbe C. Palliative treatment of disseminated malignant melanoma: a systemic review of 41 randomised clinical trials. Lancet Oncol. 2003;4:748-59.
6. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, Cooper ZA, Chapman PB, Solit DB, Ribas A, Lo RS, Flaherty KT, Ogino S, Wargo JA, Golub TR. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 2012;487:500-4.
7. Dean E, Lorigan P. Advances in the management of melanoma: targeted therapy, immunotherapy and future directions. Expert Rev Anticancer Ther. 2012;12:1437-48.
8. Rudolph BM, Groffik A, Stanger C, Loquai C, Grabbe S. Systemic therapy for malignant melanoma. Hautarzt. 2012;63:885-98.
9. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O. Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. J Gene Med. 2007;9:440-51.
10. Carvalho FR, Vassão RC, Nicoletti MA, Maria DA. Effect of Curcuma zedoaria crude extract against tumor progression and immunomodulation. J Venom Anim Toxins Incl Trop Dis. 2010;16:324-41.
11. Abusnina A, Keravis T, Yougbaré I, Bronner C, Lugnier C. Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res. 2011;55:1677-89.
12. Rivera-Espinoza Y, Muriel P. Pharmacological actions of curcumin in liver diseases or damage. Liver Int. 2009;29:1457-66.
13. Bisht S, Maitra A. Systemic delivery of curcumin: 21st century solutions for an ancient conundrum. Curr Drug Discov Technol. 2009;6:192-9.
14. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med. 1998;64:353-6.
15. Faião-Flores F, Suarez JA, Pardi PC, Maria DA. DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate: a curcumin analog with a synergic effect in combination with paclitaxel in breast cancer treatment. Tumour Biol. 2012;33:775-85.
16. Faião-Flores F, Pardi PC, Santos RP, Rando DG, Quincoces JAP, Maria DA. Antiproliferative and antimetastatic activity of DM-1, sodium 4-[5-(4-hydroxy-3-methoxyphenyl)-3-oxo-penta-1,4-dienyl]-2-methoxy-phenolate, in B16F10 melanoma. Appl Cancer Res. 2008;28:72-9.
17. Brohem CA, Massaro RR, Tiago M, Marinho CE, Jasiulionis MG, de Almeida RL, Rivelli DP, Albuquerque RC, de Oliveira TF, de Melo Loureiro AP, Okada S, Soengas MS, de Moraes Barros SB, Maria-Engler SS. Proteasome inhibition and ROS generation by 4-nerolidylcatechol induces melanoma cell death. Pigment Cell Melanoma Res. 2012;25:354-69.
18. Quincoces Suarez JA, Rando DG, Maria DA, Pardi P, Martins C, De Souza P. Methods to prepare penta-1,4-dien-3-ones and substituted cyclohexanones and derivatives and derivatives with antitumoral and antiparasitic properties, the compounds and their uses. Brazilian Patent PI 0602640-0 (06.07.2006); PCT/ BR2007/000175 (06.07.2007); WO 2008/003155.
19. Quincoces Suarez JA, Maria DA, Faião-Flores F, Rando DG, Santos RP, Pardi P. Pharmaceutical composition and use of the pharmaceutical composition for the treatment, prophylaxis or prevention of neoplastic diseases in human and animals. Brazilian Patent: PI 0902039-0; 09/06/2009; PCTBR2009/000375; 11.11.2009; WO 2010/142007; 16/12/2010.
20. Quincoces Suarez J, Rando DG, Santos RP, Gonçalves CP, Ferreira E, Carvalho J, Kohn L, Maria DA, Faião-Flores F, Michalik D, Marcucci MC, Vogel C. New antitumoral agents I: in vitro anticancer activity and in vivo acute toxicity of synthetic 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadien-3- one and derivatives. Bioorg Med Chem. 2010;18:6275-81.
21. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983;65:55-63.
22. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979;95:351-8.
23. Cheng X, Xiao Y, Wang X, Wang P, Li H, Yan H, Liu Q. Anti-tumor and pro-apoptotic activity of ethanolic extract and its various fractions from Polytrichum commune L. ex Hedw in L1210 cells. J Ethnopharmacol. 2012;143(1):49-56.
24. Brasil. Ministério da Saúde. Memento terapêutico 2007/2008. 2nd edn. Brasília; 2007.
25. Geran RI, Greenberg NH, Macdonald MM, Schumacher AM, Abbott BJ. Protocols for screening chemical agents and natural products against animal tumors and other biological systems. 3rd ed. Bethesda: National Institute of Health; 1972. p. 47-51.
26. Henmi K, Hiwatashi Y, Hikita E, Toyama N, Hirano T. Methoxy- and fluoro-chalcone derivatives arrest cell cycle progression and induce apoptosis in human melanoma cell A375. Biol Pharm Bull. 2009;32:1109-13.
27. Chen Y, Kramer DL, Diegelman P, Vujcic S, Porter CW. Apoptotic signaling in polyamine analogue-treated SK-MEL-28 human melanoma cells. Cancer Res. 2001;61:6437-44.
28. Li W, Sanki A, Karim RZ, Thompson JF, Soon Lee C, Zhuang L, McCarthy SW, Scolyer RA. The role of cell cycle regulatory proteins in the pathogenesis of melanoma. Pathology. 2006;38:287-301.
29. Ladstein R, Bachmann I, Straume O, Akslen LA. Ki-67 expression is superior to mitotic count and novel proliferation markers PHH3, MCM4 and mitosin as a prognostic factor in thick cutaneous melanoma. BMC Cancer. 2010;10:140.
30. Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF. Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat. 2007;10:218-34.
31. Srinivasan M, Sudheer AR, Rajasekaran KN, Menon VP. Effects of curcumin analog on gamma-radiation-induced cellular changes in primary culture of isolated rat hepatocytes in vitro. Chem Biol Interact. 2008;176:1-8.
32. Jagetia GC, Reddy TK. Modulation of radiation induced alterations in the antioxidant status of mice by naringin. Life Sci. 2005;77:780-94.
33. Benzie IF. Lipid peroxidation: a review of causes, consequences, measurement and dietary influences. Int J Food Sci Nutr. 1996;47:233-61.
34. Heiskanen KM, Bhat MB, Wang HW, Ma J, Nieminen AL. Mitochondrial depolarization accompanies cytochrome c release during apoptosis in PC6 cells. J Biol Chem. 1999;274:5654-8.
35. Tait SWG, Green DR. Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 2010;11:621-32.
36. Mellier G, Huang S, Shenoy K, Pervaiz S. TRAILing death in cancer. Mol Aspects Med. 2010;31:93-112.
37. Du CY, Fang M, Li YC, Li L, Wang XD. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition. Cell. 2000;102:33-42.
38. Riedl SJ, Shi Y. Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 2004;5:897-907.
39. Bill MA, Fuchs JR, Li C, Yui J, Bakan C, Benson Jr DM, Schwartz EB, Abdelhamid D, Lin J, Hoyt DG, Fossey SL, Young GS, Carson 3rd WE, Li PK, Lesinski GB. The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity. Mol Cancer. 2010;9:165.
40. Piro LD. Apoptosis, Bcl-2 antisense, and cancer therapy. Oncology (Williston Park). 2004;18:5-10.
41. Lebe B, Pabuççuoǧlu U, Ozer E. The significance of Ki-67 proliferative index and cyclin D1 expression of dysplastic nevi in the biologic spectrum of melanocytic lesions. Appl Immunohistochem Mol Morphol. 2007;15:160-4.
42. Linden MD, Torres FX, Kubus J, Zarbo RJ. Clinical application of morphologic and immunocytochemical assessments of cell proliferation. Am J Clin Pathol. 1992;97:S4-13.
43. Al-Hujaily EM, Mohamed AG, Al-Sharif I, Youssef KM, Manogaran PS, Al-Otaibi B, Al-Haza'a A, Al-Jammaz I, Al-Hussein K, Aboussekhra A. PAC, a novel curcumin analogue, has anti-breast cancer properties with higher efficiency on ER-negative cells. Breast Cancer Res Treat. 2011;128:97-107.
44. Aggarwal S, Ndinguri MW, Solipuram R, Wakamatsu N, Hammer RP, Ingram D, Hansel W. DLys(6)]-luteinizing hormone releasing hormone-curcumin conjugate inhibits pancreatic cancer cell growth in vitro and in vivo. Int J Cancer. 2011;129:1611-23. Estado de São Paulo Estado de São Paulo Estado de São Paulo